Oscar Health (OSCR) Could Be 29% Above Fair Value After Zacks Rank Upgrade
Oscar Health (OSCR) is back in focus after recent analyst reports cited substantial upward revisions in earnings estimates and a top Zacks Rank #1 rating, prompting fresh attention from both value and momentum investors.
See our latest analysis for Oscar Health.
The recent attention on Oscar Health has come alongside a sharp swing in momentum, with a 1-day share price return of 0.83% and a 7-day share price return down 4.72%, set against a 90-day share price return of 84.29% and a 1-year total shareholder return of 116.84%. Together, these figures suggest that interest has built quickly over recent months, even as shorter term trading has cooled.
If you are looking beyond Oscar Health for other healthcare technology ideas, this is a good time to scan for additional opportunities in the sector using our 39 healthcare AI stocks
Oscar Health now trades above the average analyst price target, following a recent surge that has created a clear gap between the market price and where estimates cluster. This raises the question of where fair value might really sit.
Most Popular Narrative: 29% Overvalued
Compared with the narrative fair value of $22.60, Oscar Health’s last close at $29.10 implies a rich setup that hinges on ambitious profitability and growth expectations under a 7.11% discount rate.
The analysts have a consensus price target of $22.6 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $35.0, and the most bearish reporting a price target of just $13.0.
Want to see what kind of revenue ramp and margin shift analysts are baking in for Oscar Health? The fair value case leans heavily on sharper profitability and a very specific earnings profile. Curious which long range earnings and valuation assumptions sit under that $22.60 figure? The full narrative breaks down the projections in detail.
Result: Fair Value of $22.60 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Oscar Health still faces policy and regulatory risks around the ACA market and data use, which could challenge the margin improvement that is part of that narrative.
Find out about the key risks to this Oscar Health narrative.
Another View: Oscar Health on Sales Based Valuation
The narrative fair value suggests Oscar Health is overvalued at $29.10, but the current P/S ratio of 0.7x tells a different story. That is lower than both the US Insurance industry average of 1.2x and peers at 1.3x, and it is also below a fair ratio of 0.8x, which points to a more conservative pricing of Oscar’s revenues. For investors weighing these signals, which valuation anchor feels more reasonable?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Oscar Health split between risks and rewards, this is a moment to move quickly and stress test the story yourself using our 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Oscar Health?
If Oscar Health has sharpened your focus on where capital works hardest, do not stop here. Widen your search and pressure test other opportunities with a structured approach.
- Zero in on quality at a discount by scanning our 47 high quality undervalued stocks and compare how other stocks stack up against Oscar Health on valuation and fundamentals.
- Steady your portfolio with income ideas by using the 8 dividend fortresses to spot companies pairing higher yields with consistent payout histories.
- Sleep easier at night by filtering for resilient businesses through the 84 resilient stocks with low risk scores, so you are not relying on Oscar Health alone for your risk profile.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com